Strategic Collaboration Opportunity: Partner with BIA Separations to co-develop purification and analytical platforms for mRNA pipelines, leveraging their CIM Monolithic Columns and PATfix analytics to accelerate Arnav Biotech collaboration and expand into viral vectors and mRNA therapeutics.

Technology Upsell Opportunity: Offer enhanced chromatography solutions and ligand technologies (PrimaS) to support scale up for large biomolecules, plasmid DNA, and viral vectors, aligning with their focus on high flow, high capacity purification.

Global Expansion Opportunity: Target regional expansion into Southern Europe and broader EU markets, aligning with BIA’s facility growth in Ajdovščina and their status as a global supplier to biopharma clients.

Early Stage Programs Opportunity: Propose early process development and Cornerstone/AAV service collaborations to capture new gene therapy and viral vector programs, leveraging their history of AAV process development services.

Financial Bridge Opportunity: Position modular, scalable chromatography and analytical solutions as cost-effective upgrades for small to mid-sized biopharma customers seeking robust downstream purification with rapid timeline benefits, aligned to their current revenue and funding profile.